Proteon logo     Print Page | Close Window

SEC Filings

PROTEON THERAPEUTICS INC filed this Form 10-Q on 11/07/2017
Entire Document

Proteon Therapeutics, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)



   Nine Months Ended September 30,
   2017  2016
Operating activities          
Net loss  $(24,413)  $(21,564)
Reconciliation of net loss to net cash used in operating activities:          
Depreciation   115    87 
Amortization of premium/discount on available-for-sale securities   (2)   108 
Unrealized gain on forward foreign currency contracts included in net income   -    (127)
Foreign currency remeasurement gain   196    (6)
Stock-based compensation   2,459    2,499 
Changes in:          
Prepaid expenses and other assets   1,049    (20)
Interest receivable   (73)   46 
Accounts payable, accrued expenses and other current liabilities   4,015    869 
Net cash used in operating activities   (16,654)   (18,108)
Investing activities          
Purchases of available-for-sale investments   (31,443)   (39,756)
Proceeds from maturities of available-for-sale investments   8,920    44,603 
Purchase of property and equipment   (23)   (259)
Net cash (used in) provided by investing activities   (22,546)   4,588 
Financing activities          
Exercise of stock options   109    156 
Proceeds from issuance of common stock under ESPP   58    5 
Proceeds from issuance of common stock, net of issuance costs   1,287    - 
Proceeds from the issuance of Series A redeemable convertible preferred stock, net of issuance costs   21,536    - 
Net cash provided by financing activities   22,990    161 
Effect of exchange rate changes on cash   (196)   6 
Decrease in cash and cash equivalents   (16,406)   (13,353)
Cash and cash equivalents, beginning of period   36,392    40,031 
Cash and cash equivalents, end of period  $19,986   $26,678 
Supplemental disclosure of non-cash investing and financing activities          
Accretion of convertible preferred stock  $6,747   $- 



The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.